Effect of Visualization of Functional Milk Efficacy on Perceived Benefits

Exclusion Criteria

• •1. Pre-existing chronic medical condition and/or history of significant medical condition (e.g. malignancy, significant organ dysfunction, autoimmune and/ or genetic disease, gastrointestinal disease, endocrine disease (e.g. diabetes mellitus, history of hypoglycemia, polycystic disease syndrome, Addison's disease, Cushing's syndrome, acromegaly), acute or chronic infectious condition (e.g. hepatitis B and C, HIV, tuberculosis), cardiovascular disease (heart failure, angina, myocardial infarction, stroke), renal disease (renal insufficiency), hepatic (liver cirrhosis, liver failure) or respiratory disease (COPD), hematological disorder (e.g. anemia), neurological and/or psychiatric conditions (e.g. depression, psychotic disorders, chronic insomnia eating disorder), as diagnosed by the treating physician, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
• •2. Any acute illness or any recent medical/ surgical intervention within 3 months prior to enrolment potentially interfering with study procedures and assessments.
• •3. Known or suspected cow's milk protein allergy (CMPA), lactose and /or soy intolerance /hypersensitivity.
• •4. Known substance abuse or alcohol user exceeds following intake on a regular basis, alcohol intake \> 2 servings per day for males and \> 1 servings per day for females. A serving is 40ml of strong alcohol, 100 ml of red or white wine, or 300 ml of beer.
• •5. Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
• •6. Patients with refractory hypertension, and patients with hypertension who are taking antihypertensive drugs (beta-blockers, thiazide diuretics) that may affect blood glucose metabolism.
• •7. Female participants currently on hormonal therapy including post-menopausal hormone Replacement Therapy (PRT) or have been on PRT treatment in the past two months before study participation.
• •8. Participants on systemic corticosteroids, glucocorticoids, or cyclosporine A.
• •9. Female participants who are pregnant or intending to become pregnant, lactating and or breastfeeding.
• •10. Participants who had a significant weight loss (≥5%) within the last 6 months or follow a weight loss programme.
• •11. Following diets with low carbohydrate content (e.g., ketogenic diet, Atkins diet, low-carb diet, carb cycling diet), intermittent fasting, breakfast skippers or any self-restricted, controlled, or special therapeutic diet.
• •12. Participants who do not regularly (≤ 3 times per week) drink dairy milk.
• •13. Use of multivitamin/ multimineral supplements (including vitamin C, supplements fiber-based or derived of leaf extracts or known to/intended to lower blood glucose as per package claim) up to 15 days prior to screening.
• •14. Medically known cutaneous hypersensitivity to adhesives, silicon watchstrap and plasters.
• •15. High daily coffee consumption (≥400 mg of caffeine/day, equivalent to ≥4 cups of coffee).
• •16. Currently participating in another interventional clinical study.
• •17. Having two (or more) participants from the same household already enrolled in the study.